AYTU
Aytu BioPharma, Inc.2.4200
+0.0900+3.86%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q2 '26
Early launch feedback, weather cleared
Q&A revealed early ExuA prescribers targeting tough MDD cases hit by sexual side effects or weight gain, drawn to its novel MOA and RxConnect's low barriers. Management nixed near-term salesforce expansion without cash flow backing, avoiding dilution. Snowmageddon crushed two full field weeks, delaying fills and reps, but supply cleared fast with ample inventory for ramp. Scripts mostly hit RxConnect from commercial payers, even sans reps in some states. Answers reaffirmed prepared optimism sans contradictions. Investors eye refill traction past trial packs.
Key Stats
Market Cap
24.66MP/E (TTM)
-Basic EPS (TTM)
-2.23Dividend Yield
0%Recent Filings
8-K
Q2 revenue dips on EXXUA launch
Aytu BioPharma posted Q2 fiscal 2026 net revenue of $15.2 million, down from $16.2 million last year, as ADHD and pediatric portfolios dipped amid EXXUA launch ramp-up. EXXUA, now stocked nationwide, added $0.2 million in initial sales; sales force of 40+ targets high-MDD zones. Cash holds at $30.0 million. Adjusted EBITDA swung to $(0.8) million on launch spends.
10-Q
Q2 FY2026 results
Aytu BioPharma posted Q2 FY2026 revenue of $15.2M, down 7% y/y from $16.2M yet up sharply q/q (derived), as ADHD Portfolio dipped to $13.2M from $13.8M while EXXUA launched with $0.2M. Gross margin slipped to 63% from 66% on inventory write-downs, fueling a $2.0M operating loss versus $1.7M last year; net loss hit $10.6M, widened by $8.2M derivative warrant mark-to-market loss. Cash generated $3.1M from operations less $17K capex for ~$3.0M FCF YTD, ending with $30.0M cash against $9.1M revolver draw and $12.1M term debt (SOFR+7%, due 2029). Warrants stay anti-dilutive. Generic Adzenys litigation drags into 2027.
8-K
EXXUA Investor Day recap
Aytu BioPharma recapped its January 20, 2026 Investor Day, spotlighting EXXUA, the first 5-HT1a agonist for MDD launched December 15, 2025. KOLs highlighted superior efficacy versus SSRIs/SNRIs, neutral sexual and weight profiles, with Phase 3 trials showing statistically significant HAM-D17 improvements. Early prescriptions signal launch traction; Fabre-Kramer deal yields 28% royalties. Cash burn stays low.
8-K
Stockholders reelect full board
Aytu BioPharma stockholders convened their 2026 annual meeting on December 10, 2025, with 60% quorum. All five directors—Disbrow, Donofrio, Dockery, Jain, and Liu—won reelection by majority votes despite some withholdings. Shareholders ratified Grant Thornton as auditors for fiscal 2026 and backed executive pay on advisory basis. Board continuity locked in.
10-Q
Q1 FY2026 results
Aytu BioPharma posted Q1 FY2026 revenue of $13.9M, down 16% y/y from $16.6M yet steady q/q, with gross profit at $9.2M (66.1% margin) versus 72.3% last year; operating loss widened to $1.5M from $0.9M as selling expenses ticked down but amortization persisted. Derivative warrant gains of $3.8M flipped continuing ops to $2.0M net income, though diluted EPS fell anti-dilutive to -$0.08 on 19.5M shares. Cash climbed to $32.6M, revolving facility at $14.9M (matures 2029, compliant), term debt $12.3M. EXXUA commercialization rights await Q2 FY2026 launch. Cash burns less. Patent suit over Adzenys generic looms to 2027.
IPO
Website
Employees
Sector
Industry
AMRX
Amneal Pharmaceuticals, Inc.
12.17-0.29
ANIP
ANI Pharmaceuticals, Inc.
81.10-0.41
AVDL
Avadel Pharmaceuticals plc
21.37-0.05
AYRWF
AYR WELLNESS INC.
0.03+0.01
ELTP
Elite Pharmaceuticals, Inc.
0.50+0.00
NXEN
Nexien BioPharma, Inc.
0.00+0.00
RGC
Regencell Bioscience Holdings L
16.70-0.56
TEVA
Teva Pharmaceutical Industries
30.10-0.03
TLPH
Talphera, Inc.
1.20+0.02
VTRS
Viatris Inc.
11.46-0.20